AC-0025

N/A

Report date: 2022/01/05 15:24:33
NME

Base Information

Drug NameAC-0025
Drug Alias NameAC-0025
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase JAK3 inhibitorsTyrosine-protein kinase BTK inhibitors
TargetsTyrosine-protein kinase BTKTyrosine-protein kinase JAK3
Therapy Area/IndicationsArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesHangzhou Acea Pharmaceutical Research Co LtdSorrento Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesSorrento Therapeutics IncHangzhou Acea Pharmaceutical Research Co Ltd
Inactive CompaniesN/A
Active IndicationsArthritis, Rheumatoid
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A